Recherche
-
Will the future of pharmacovigilance be more automated?
(Expert Opinion on Drug Safety. vol. 22, n° 7, pp. 541-548, 2023-07-01)Article de revue -
Antipsychotics and risk of QT prolongation: a pharmacovigilance study
(Psychopharmacology. vol. 240, pp. 199-202, 2022-12-14)Article de revue -
Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy
(Thérapie, 2021-04-02)Article de revue -
Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase
(Pharmaceuticals (Basel). vol. 16, n° 10, pp. 1420, 2023-10-05)Article de revueLibre accès -
Adverse Drug Reaction-Related to Drug Shortage: A Retrospective Study on the French National Pharmacovigilance Database
(British Journal of Clinical Pharmacology. vol. 89, n° 3, pp. 1080-1088, 2023-03)Article de revueLibre accès -
Interpretation of Pharmacovigilance Disproportionality Analyses
(Clinical Pharmacology and Therapeutics, 2023-05-30)Article de revue -
Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study
(The Lancet Regional Health - Europe. vol. 17, 2022-06)Article de revueLibre accès -
Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines
(Drug Safety. vol. 43, n° 11, pp. 1089-1104, 2020)Article de revueLibre accès -
Medicine misuse: A systematic review and proposed hierarchical terminology
(British Journal of Clinical Pharmacology, 2020-12-08)Article de revue -
Repenser la prise en charge des sujets âgés atteints d’un cancer : propositions du groupe Priorités Âge Cancer
(Bulletin du Cancer. vol. 109, n° 6, pp. 714-721, 2022-06)Article de revue